Suresh Senan

1997–2025 年に発表

164
論文数
36,202
被引用数
95
h 指数
152
i10 指数

被引用数

Suresh Senan の年別被引用数1994 年: 被引用 3 件1995 年: 被引用 4 件1996 年: 被引用 1 件1999 年: 被引用 1 件2000 年: 被引用 3 件2001 年: 被引用 11 件2002 年: 被引用 15 件2003 年: 被引用 14 件2004 年: 被引用 39 件2005 年: 被引用 43 件2006 年: 被引用 46 件2007 年: 被引用 56 件2008 年: 被引用 50 件2009 年: 被引用 74 件2010 年: 被引用 141 件2011 年: 被引用 131 件2012 年: 被引用 113 件2013 年: 被引用 160 件2014 年: 被引用 194 件2015 年: 被引用 214 件2016 年: 被引用 235 件2017 年: 被引用 218 件2018 年: 被引用 208 件2019 年: 被引用 1,108 件2020 年: 被引用 1,394 件2021 年: 被引用 1,308 件2022 年: 被引用 942 件2023 年: 被引用 700 件2024 年: 被引用 1,184 件2025 年: 被引用 446 件2026 年: 被引用 7 件1997〜1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,176 件、この内訳の 18.7%中国: 引用元論文 1,200 件、この内訳の 10.3%オランダ: 引用元論文 772 件、この内訳の 6.6%イタリア: 引用元論文 759 件、この内訳の 6.5%イギリス: 引用元論文 700 件、この内訳の 6%ドイツ: 引用元論文 692 件、この内訳の 5.9%カナダ: 引用元論文 545 件、この内訳の 4.7%フランス: 引用元論文 509 件、この内訳の 4.4%スペイン: 引用元論文 405 件、この内訳の 3.5%スイス: 引用元論文 390 件、この内訳の 3.4%日本: 引用元論文 386 件、この内訳の 3.3%オーストラリア: 引用元論文 341 件、この内訳の 2.9%
0%18.7%その他 23.8%

分野

  • Medicine77.7%
  • Physics and Astronomy10.4%
  • Biochemistry, Genetics and Molecular Biology7.8%
  • Immunology and Microbiology0.9%
  • Engineering0.8%
  • Computer Science0.6%
  • その他1.8%

トピック

  • Lung Cancer Diagnosis and Treatment12.7%
  • Lung Cancer Treatments and Mutations9.5%
  • Advanced Radiotherapy Techniques6.9%
  • Lung Cancer Research Studies6.4%
  • Cancer Immunotherapy and Biomarkers5.9%
  • Radiomics and Machine Learning in Medical Imaging4%
  • その他54.6%

共著者

全論文

検索で開く
  1. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 1,295

  2. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    著者: , , , , , , , - Annals of Oncology 2017 被引用: 2,335

  3. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

    著者: , , , , , , , , , , , , , , , , , , , , , - The Lancet 2019 被引用: 1,859

  4. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    著者: , , , , , , , , , , , , - Annals of Oncology 2016 被引用: 2,636

  5. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 被引用: 275

  6. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 被引用: 1,459

  7. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial

    著者: , , , , , , , , - The Lancet 2014 被引用: 592

  8. Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review

    著者: , , , , , , , , , , - Radiation Oncology 2020 被引用: 235

  9. Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysis

    著者: , , , , , , , , , , , , - International Journal of Radiation Oncology*Biology*Physics 2013 被引用: 674

  10. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

    著者: , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2020 被引用: 224

  11. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2021 被引用: 468

  12. Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer

    著者: , , , , , , , , , - New England Journal of Medicine 2007 被引用: 1,128

  13. Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2024 被引用: 129

  14. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes

    著者: , , , , , , , , , , , , , , , , , , , , , - International Journal of Radiation Oncology*Biology*Physics 2022 被引用: 202

  15. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Egbert F. Smit, Peter Meldgaard, Alex A. Adjei, M. Nicolson, Lucio Crinò, Paul Van Schil, Suresh Senan, Corinne Faivre‐Finn, Gaetano Rocco, Paolo Veronesi, Jean-Yves Douillard, Eric Lim, Christophe Dooms, W. Weder, Dirk De Ruysscher, C. Le Péchoux, Paul De Leyn, Virginie Westeel - Annals of Oncology 2014 被引用: 495

  16. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer

    著者: , , , , , , , , , , - Radiotherapy and Oncology 2017 被引用: 348

  17. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - BMC Cancer 2019 被引用: 268

  18. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 437

  19. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline

    著者: , , , , , , , , , , , , , , , , , , , , , , - Practical Radiation Oncology 2023 被引用: 109

  20. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

    著者: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2011 被引用: 712

  21. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rafał Dziadziuszko, Solange Peters, Ramón Rami Porta, Johan Vansteenkiste, Christophe Dooms, Dirk De Ruysscher, Benjamin Besse, Silvia Novello - Journal of Thoracic Oncology 2019 被引用: 292

  22. Same-day adaptive palliative radiotherapy without prior CT simulation: Early outcomes in the FAST-METS study

    著者: , , , , , , , , , , - Radiotherapy and Oncology 2023 被引用: 75

  23. An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , - Clinical Lung Cancer 2014 被引用: 438

  24. Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer

    著者: , , , , , , - Radiotherapy and Oncology 2017 被引用: 313